A phase IIb study of selinexor in combination with carfilzomib, daratumumab, or pomalidomide in patients with multiple myeloma relapsing on current therapy.

person Noa Biran John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ info_outline Noa Biran, David H. Vesole, Harsh V. Parmar, Pooja Phull, Kimberley Doucette, Rena Feinman, Joshua Zenreich, Palka Anand, Kristin Ivanovski, Monique Pace, Genevieve Breeze, Rania Amer, Lisa Biamonte, Adolfo Aleman, Rashmi Unawane, Elizabeth Pendergrass, Alexandra Della Pia, Susan Kumka, David Samuel DiCapua Siegel

Authors person Noa Biran John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ info_outline Noa Biran, David H. Vesole, Harsh V. Parmar, Pooja Phull, Kimberley Doucette, Rena Feinman, Joshua Zenreich, Palka Anand, Kristin Ivanovski, Monique Pace, Genevieve Breeze, Rania Amer, Lisa Biamonte, Adolfo Aleman, Rashmi Unawane, Elizabeth Pendergrass, Alexandra Della Pia, Susan Kumka, David Samuel DiCapua Siegel Organizations John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ Abstract Disclosures Research Funding Pharmaceutical/Biotech Company Karyopharm Therapeutics, Inc. Background: Selinexor is an oral, selective inhibitor of nuclear export compound that blocks exportin 1 (XPO1), leading to retention of tumor suppressor proteins and apoptosis in malignant cells. Preclinical studies suggest synergistic activity when selinexor is combined with other treatments for MM. We hypothesize the addition of selinexor can recapture response to patients relapsing or refractory on carfilzomib (CFZ), pomalidomide (POM) or daratumumab (DARA)-based regimens. Methods: This is an ongoing phase IIb, open-label, multicenter study to evaluate the safety and efficacy of selinexor plus CFZ, POM, or DARA in patients with MM. Patients were enrolled to each arm only if their disease was refractory to the specific drug of interest (CFZ for Arm 1, POM for Arm 2, and DARA for Arm 3). Arm 1 (n=1) consists of selinexor 80 mg orally on D1, 8, 15; CFZ 56 mg/m2 IV on D1, 8, 15; and dexamethasone (DEX) on D1, 8, 15, 22. Arm 2 (n=7) consists of selinexor 60 mg orally on D1, 8, 15; POM 4 mg orally on D1-21; and DEX on D1, 8, 15, 22. Arm 3 (n=7) consists of selinexor 100 mg orally on D1, 8, 15, 22; DARA 16 mg/kg IV or 1,800 mg SQ on D1, 8, 15, 22 for C1-2; D1 and 15 for C3-6; D1 for ≥C7; and DEX on D1, 8, 15, 22. The primary endpoint is ORR and secondary endpoints include PFS, OS, MRD negativity and TEAEs. Results: At data cutoff (Feb 6 2023), 15 patients were enrolled with a median age of 64 years (range 60-83), 27% with ISS stage III MM, 73% with high-risk cytogenetics, 93% refractory to the last LOT, 47% triple refractory, and 33% quadruple refractory (Table). The ORR was 33% (4/12; 4 PR) and the CBR was 92% (11/12; 7 SD); 3 patients are pending. The most common grade 3-4 TEAEs (n=34) were neutropenia (32%), hypophosphatemia (9%), pneumonia (6%), hyperglycemia (6%), and fatigue (6%). Ten patients discontinued treatment due to PD (n=5), withdrawal of consent (n=2), or TEAEs (n=3; fall, diarrhea, and RSV pneumonia), of whom 1 patient died while hospitalized for diarrhea and weakness. Conclusions: Preliminary results show selinexor plus CFZ, POM, or DARA is safe and restores sensitivity to therapy in relapsed/refractory MM patients. In this population of heavily pretreated MM patients, the ORR (33%) and CBR (92%) observed are higher compared to those seen with single-agent selinexor (ORR 4% and CBR 21%) (Chen C et al, Blood 2018). Clinical trial information: NCT04661137. Patient characteristics. Characteristic Patients on trial N=15 no. (%) Age, median years (range) 64 (60-83) Male 9 (60) Race Asian Black or African American White Other 3 (20) 2 (13) 8 (54) 2 (13) International staging system (ISS) ISS-1 ISS-2 ISS-3 Unavailable 4 (27) 6 (40) 4 (27) 1 (6) High-risk cytogenetics 11 (73) Prior treatments Bortezomib Carfilzomib Daratumumab Pomalidomide Revlimid 9 (60) 10 (67) 12 (80) 13 (80) 15 (100) LOT, median (range) 3 (2-6) Refractory to last LOT 14 (93) Triple refractory 7 (47) Quadruple refractory 5 (33)

Clinical